Medicines
We are committed to expanding our portfolio and our pipeline in therapeutic areas that can leverage our unique expertise and growing our global footprint.
At Jazz, we pride ourselves on boldly taking on challenging, complex diseases and introducing new, transformative therapeutic solutions. We do that by keeping patients and their families at the center of all that we do and forging connections between patients and science.
Rare Sleep Disorders and Rare Epilepsies
As a long-time leader in sleep medicine, Jazz has been at the forefront of providing therapies and support for people living with rare sleep disorders including idiopathic hypersomnia and narcolepsy. We have expanded into rare epilepsies, strengthening our commitment to patient populations with high unmet needs, including Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. We provide novel, life- changing medicines for people living with rare conditions, and we continue to expand our reach and capabilities to discover and develop new therapies that help people redefine what is possible in their lives.
We prioritize developing new medicines where others have not, to benefit people with limited options. For most of the disease areas within Jazz’s focus, there were either no suitable treatment options or limited effective treatment options until we developed or made one available. Learn more about our R&D.
Rare Cancer
As we advance our work in oncology, we continue to focus on people for whom we can have the greatest impact, developing therapies that have the potential to save lives or enable people to live longer, healthier lives. Our focus is in the areas of extensive stage small cell lung cancer, biliary tract cancer, diffuse midline glioma, acute leukemias, both lymphocytic and myeloid (ALL and AML), and for patients who develop an ultra-rare complication of hematopoietic stem cell transplantation (HSCT), known as veno-occlusive disease (VOD).
While the oncology community is large, as part of our commitment to patient populations with high unmet needs, we have honed in on smaller groups of people and pediatric patients facing unique challenges. These patients face difficult odds, with limited treatment options and limited survival from rare cancers, including solid tumors and blood cancers. Learn more about our R&D.
Our Medicines
Learn more about Our Medicines.